Literature DB >> 30884545

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Max-Joseph Grimm1,2, Gesine Respondek1,2, Maria Stamelou3, Thomas Arzberger2,4,5, Leslie Ferguson6, Ellen Gelpi7,8, Armin Giese4, Murray Grossman9, David J Irwin9, Alexander Pantelyat10, Alex Rajput6, Sigrun Roeber4, John C van Swieten11, Claire Troakes12, Angelo Antonini13, Kailash P Bhatia14, Carlo Colosimo15, Thilo van Eimeren16, Jan Kassubek17, Johannes Levin2,18, Wassilios G Meissner19,20,21, Christer Nilsson22, Wolfgang H Oertel23, Ines Piot1,2, Werner Poewe24, Gregor K Wenning24, Adam Boxer25, Lawrence I Golbe26, Keith A Josephs27, Irene Litvan28, Huw R Morris29, Jennifer L Whitwell30, Yaroslau Compta31, Jean-Christophe Corvol32, Anthony E Lang33, James B Rowe34, Günter U Höglinger1,2.   

Abstract

BACKGROUND: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.
METHODS: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.
RESULTS: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.
CONCLUSIONS: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  autopsy; diversity; phenotype; progressive supranuclear palsy

Mesh:

Year:  2019        PMID: 30884545      PMCID: PMC6699888          DOI: 10.1002/mds.27666

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 3.  Invited review: Neuropathology of tauopathies: principles and practice.

Authors:  G G Kovacs
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

Review 4.  Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Authors:  Gesine Respondek; Carolin Kurz; Thomas Arzberger; Yaroslau Compta; Elisabet Englund; Leslie W Ferguson; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Christer Nilsson; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Jennifer L Whitwell; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Jean-Christophe Corvol; Carlo Colosimo; Richard Dodel; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw Morris; Peter Nestor; Wolfgang H Oertel; Gil D Rabinovici; James B Rowe; Thilo van Eimeren; Gregor K Wenning; Adam Boxer; Lawrence I Golbe; Irene Litvan; Maria Stamelou; Günter U Höglinger
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

Review 5.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

6.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

7.  The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases.

Authors:  Gesine Respondek; Maria Stamelou; Carolin Kurz; Leslie W Ferguson; Alexander Rajput; Wan Zheng Chiu; John C van Swieten; Claire Troakes; Safa Al Sarraj; Ellen Gelpi; Carles Gaig; Eduardo Tolosa; Wolfgang H Oertel; Armin Giese; Sigrun Roeber; Thomas Arzberger; Stefan Wagenpfeil; Günter U Höglinger
Journal:  Mov Disord       Date:  2014-11-05       Impact factor: 10.338

  7 in total
  33 in total

1.  Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.

Authors:  Andrea Horta-Barba; Javier Pagonabarraga; Saül Martínez-Horta; Laura Busteed; Berta Pascual-Sedano; Ignacio Illán-Gala; Juan Marin-Lahoz; Ignacio Aracil-Bolaños; Jesús Pérez-Pérez; Frederic Sampedro; Helena Bejr-Kasem; Jaime Kulisevsky
Journal:  J Neurol       Date:  2021-03-11       Impact factor: 4.849

2.  Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.

Authors:  Gesine Respondek; Max-Joseph Grimm; Ines Piot; Thomas Arzberger; Yaroslau Compta; Elisabet Englund; Leslie W Ferguson; Ellen Gelpi; Sigrun Roeber; Armin Giese; Murray Grossman; David J Irwin; Wassilios G Meissner; Christer Nilsson; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Günter U Höglinger
Journal:  Mov Disord       Date:  2019-09-30       Impact factor: 10.338

Review 3.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

4.  Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.

Authors:  Sarah M Bower; Stephen D Weigand; Farwa Ali; Heather M Clark; Hugo Botha; Julie A Stierwalt; Jennifer L Whitwell; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2021-12-31

5.  The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study.

Authors:  Zeynep Idil Seckin; Joseph R Duffy; Edythe A Strand; Heather M Clark; Rene L Utianski; Mary M Machulda; Hugo Botha; Farwa Ali; Nha Trang Thu Pham; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2020-10-07       Impact factor: 4.891

6.  Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Authors:  Ali Shoeibi; Irene Litvan; Jorge L Juncos; Yvette Bordelon; David Riley; David Standaert; Stephen G Reich; David Shprecher; Deborah Hall; Connie Marras; Benzi Kluger; Nahid Olfati; Joseph Jankovic
Journal:  Parkinsonism Relat Disord       Date:  2019-10-14       Impact factor: 4.891

7.  An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

Authors:  Jennifer L Whitwell; Chase A Stevens; Joseph R Duffy; Heather M Clark; Mary M Machulda; Edythe A Strand; Peter R Martin; Rene L Utianski; Hugo Botha; Anthony J Spychalla; Matthew L Senjem; Christopher G Schwarz; Clifford R Jack; Farwa Ali; Anhar Hassan; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2019-05-29

8.  Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice.

Authors:  Farwa Ali; Hugo Botha; Jennifer L Whitwell; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2019-07-24

Review 9.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

10.  Gait Analysis in Progressive Supranuclear Palsy Phenotypes.

Authors:  Marina Picillo; Carlo Ricciardi; Maria Francesca Tepedino; Filomena Abate; Sofia Cuoco; Immacolata Carotenuto; Roberto Erro; Gianluca Ricciardelli; Michela Russo; Mario Cesarelli; Paolo Barone; Marianna Amboni
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.